Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Pfizer’s first new ADC from Seagen buy fails ph. 3 NSCLC trial
The potential first-in-class ADC failed to significantly improve overall survival compared with docetaxel in previously treated nonsquamous NSCLC.
Angus Liu
Jun 23, 2026 7:15am
How Daiichi Sankyo plans to stay ahead in the ADC game
Jun 17, 2026 6:00pm
Innovent, fresh from $1.2B deal, posts key win for CLDN18.2 ADC
Jun 4, 2026 7:47am
Fierce Pharma
At ASCO, China biotech industry cements its coming of age
Jun 3, 2026 8:50am
ASCO: BMS' bispecific ADC puts TROP2 drugs on notice
Jun 2, 2026 8:00am
Rallybio swerves past Candid pothole to land deal with Avenzo
Jun 1, 2026 9:09am
